Share This Article:

Alpha Defensins Genes and Vulvovaginal Candidiasis: A Study of Cases

Abstract Full-Text HTML XML Download Download as PDF (Size:377KB) PP. 487-493
DOI: 10.4236/ojog.2015.59071    2,939 Downloads   3,364 Views   Citations

ABSTRACT

Objective: To evaluate the alpha-defensin (α-DF) genes polymorphism in women with vulvovaginal candidiasis and recurrence. Methods: This observational study included clinical vaginal secretion samples collected over four years from 88 women, ranging in age from 18 to 65 years, from medical centers of Sao Paulo and Mogi das Cruzes, Brazil. Thirty-six of these women were asymptomatic (control group) and 52 presented clinical condition compatible with vulvovaginitis (38 primary or episodic as non-recurrent forms, and 14 recurrent vulvovaginal candidiasis). A portion of each sample was plated on Sabouraud dextrose agar with chloramphenicol and grown on CHROMagar Candida for presumptive characterization. The identification of the species was obtained by sequencing of the ITS1 region of rDNA. α-DF genes were amplified for subsequent evaluation of polymorphisms by endonuclease restriction assay. Results: From 88 samples were isolated 60 Candida albicans and 28 non-albicans Candida spp. Resistant C. albicans strains and non-albicans Candida spp. were more prevalent in recurrence. In all groups, the number of resistant non-albicans Candida spp. was most high than susceptible strains. α-DF1, α-DF3 and α-DF1/α-DF3 genotypes were found in 32 (36.4%), 17 (19.3%), 6 (6.8%) vaginal samples, respectively. About 33 samples were not amplified. Recurrence and severe disease were more observed in homozygous population. Conclusions: Non-albicans Candida spp. and homozygotic α-DF genotipes (α-DF1 and α-DF3) were more related with severe clinical signs and recurrence. Further studies about vulvovaginal candidiasis and α-DF genes are necessary to access the more comprehensive role of defensins in clinical manifestations.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Boatto, H. , Francisco, E. , Kleine, J. , Silva, I. , Girão, M. , Machado, A. and Fischman, O. (2015) Alpha Defensins Genes and Vulvovaginal Candidiasis: A Study of Cases. Open Journal of Obstetrics and Gynecology, 5, 487-493. doi: 10.4236/ojog.2015.59071.

References

[1] Alvares, C.A., Svidzinski, T.I.E. and Consolaro, M.E.L. (2007) Vulvovaginal Candidiasis: Susceptibility Factors of the Host and Virulence of the Yeasts. Jornal Brasileiro de Patologia e Medicina Laboratorial, 43, 319-327.
http://dx.doi.org/10.1590/S1676-24442007000500004
[2] Rosa M.I. and Rumel, D. (2004) Fatores associados a candidíase vulvovaginal: Estudo exploratório. Revista Brasileira de Ginecologia e Obstetrícia, 26, 65-70.
http://dx.doi.org/10.1590/S0100-72032004000100010
[3] Rylander, E., Berglund, A.L., Krassny, C. and Petrini, B. (2004) Vulvovaginal Candida in a Young Sexually Active Population: Prevalence and Association with Oro-Genital Sex and Frequent Pain at Intercourse. Sexually Transmitted Infections, 80, 54-57.
http://dx.doi.org/10.1136/sti.2003.004192
[4] Caiyan, X., Weiyuan, Z., Minghui, W. and Songwen, Z. (2012) Prevalence and Risk Factors of Lower Genital Tract Infections among Women in Beijing, China. The Journal of Obstetrics and Gynaecology Research, 38, 310-315.
[5] Correa, P.R., David, P.R.S., Peres, N.P., Cunha, K.C. and Almeida, M.T.G. (2009) Phenotypic Characterization of Yeasts Isolated from the Vaginal Mucosa in Adult Women. Revista Brasileira de Ginecologia e Obstetrícia, 31, 177-181.
http://dx.doi.org/10.1590/S0100-72032009000400004
[6] Gunther, L.S., Martins, H.P., Gimenes, F., Abreu, A.L., Consolaro, M.E. and Svidzinski, T.I. (2014) Prevalence of Candida albicans and Non-Albicans Isolates from Vaginal Secretions: Comparative Evaluation of Colonization, Vaginal Candidiasis and Recurrent Vaginal Candidiasis in Diabetic and Non-Diabetic Women. Sao Paulo Medical Journal, 132, 116-120.
http://dx.doi.org/10.1590/1516-3180.2014.1322640
[7] Mnichowska-Polanowskai, M., Wojciechowska-Koszko, I., Klimowicz, B., et al. (2013) Endogenous or Exogenous Origin of Vaginal Candidiasis in Polish women? Polish Journal of Microbiology, 82, 532-543.
[8] Corsello, S. (2003) An Epidemiological Survey of Vulvovaginal Candidiasis in Italy. European Journal of Obstetrics & Gynecology and Reproductive Biology, 110, 66-72.
http://dx.doi.org/10.1016/S0301-2115(03)00096-4
[9] Douglas, L.J. (2003) Candida Biofilms and Their Role in Infection. Trends in Microbiology, 11, 30-36.
http://dx.doi.org/10.1016/S0966-842X(02)00002-1
[10] Pádua, R.A.F., Guilhermetti, E. and Svidzinski, T.I.E. (2003) In Vitro Activity of Antifungal Agents on Yeasts Isolated from Vaginal Secretion. Acta Scientiarum, Health Sciences, 25, 51-54.
[11] Ferrazza, M.H.S.H., Maluf, M.L.F., Consolaro, M.E.L., Shinobu, C.S., Svidzinski, T.I.E. and Batista, M.R. (2005) Characterization of Yeasts Isolated from the Vagina and Their Association with Vulvovaginal Candidiasis in Two Cities in Southern Brazil. Revista Brasileira de Ginecologia e Obstetrícia, 27, 58-63.
http://dx.doi.org/10.1590/S0100-72032005000200003
[12] Spacek, J., Buchta, V., Jilek, P. and Forstl, M. (2007) Clinical Aspects and Luteal Phase Assesment in Patients with Recurrent Vulvovaginal Candidiasis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 48, 165-171.
[13] Hong, E., Dixit, S., Fidel, P.L., Bradford, J. and Fischer, G. (2014) Vulvovaginal Candidiasis as a Chronic Disease: Diagnostic Criteria and Definition. Journal of Lower Genital Tract Disease, 18, 31-38.
http://dx.doi.org/10.1097/LGT.0b013e318287aced
[14] Ehrstrom, S.M., Kornfeld, D., Thuresson, J. and Rylander, E. (2005) Signs of Chronic Stress in Women with Recurrent Candida Vulvovaginitis. American Journal of Obstetrics & Gynecology, 193, 1376-1381.
http://dx.doi.org/10.1016/j.ajog.2005.03.068
[15] Fleming, D.C. (2003) Hormonal Contraception Can Suppress Natural Antimicrobial Gene Transcription in Human Endometrium. Fertility and Sterility, 79, 856-863.
http://dx.doi.org/10.1016/S0015-0282(02)04930-0
[16] Ziarrusta, G.B. (2002) Vulvovaginitis Candidiásica. Revista Iberoamericana de Micología, 19, 22-24.
[17] Barbedo, L.S. and Sgarbi, D.B.G. (2010) Candidíase. DST. Jornal Brasileiro de Doencas Sexualmente Transmissíveis, 22, 22-38.
[18] Ding, J., Chou, Y.Y. and Chang, T.L. (2009) Defensins in Viral Infections. Journal of Innate Immunity, 1, 413-420.
http://dx.doi.org/10.1159/000226256
[19] Vega, A., Ventura, I. and Chamorro, C. (2011) Neutrophil Defensins: Their Possible Role in Allergic Asthma. Journal of Investigational Allergology and Clinical Immunology, 21, 38-43.
[20] Suarez-Carmona, M., Hubert, P., Delvenne, P. and Herfs, M. (2015) Defensins: “Simple” Antimicrobial Peptides or Broad-Spectrum Molecules? Cytokine & Growth Factor Reviews, 26, 361-70.
http://dx.doi.org/10.1016/j.cytogfr.2014.12.005
[21] Smith, J.G. and Nemerow, G.R. (2008) Mechanisms of Adenovirus Neutralization by Human Alpha Defensins. Cell Host Microbe, 3, 11-19.
http://dx.doi.org/10.1016/j.chom.2007.12.001
[22] Wehkamp, J., Wang, G., Kübler, I., et al. (2007) The Paneth Cell Alpha-Defensin Deficiency of Ileal Crohn’s Disease Is Linked to Wnt/Tcf-4. The Journal of Immunology, 179, 3109-3118.
http://dx.doi.org/10.4049/jimmunol.179.5.3109
[23] Jurevic, R.J., Bai, M., Chadwick, R.B., White, T.C. and Dale, B.A. (2003) Single-Nucleotide Polymorphisms (SNPs) in Human Beta-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type 1 Diabetics and Nondiabetics Controls. Journal of Clinical Microbiology, 41, 90-96.
http://dx.doi.org/10.1128/JCM.41.1.90-96.2003
[24] Vylkova, S., Nayyar, N., Li, W. and Edgerton, M. (2007) Human Beta-Defensins Kill Candida albicans in an Energy-Dependent and Salt-Sensitive Manner without Causing Menbrane Disruption. Antimicrobial Agents and Chemotherapy, 51, 154-161.
http://dx.doi.org/10.1128/AAC.00478-06
[25] Fan, S.R., Liu, X.P. and Liao, Q.P. (2008) Human Defensins and Cytokines in Vaginal Lavage Fluid of Women with Bacterial Vaginosis. International Journal of Gynecology & Obstetrics, 103, 50-54.
http://dx.doi.org/10.1016/j.ijgo.2008.05.020
[26] Krishnakumari, V., Rangaraj, N. and Nagaraj, R. (2009) Antifungal Activities of Human Beta Defensins HBD-1 to HBD-3 and Their c-Terminal Analogs Phd1 to Phd3. Antimicrobial Agents and Chemotherapy, 53, 256-260.
http://dx.doi.org/10.1128/AAC.00470-08
[27] Levinson, P., Kaul, R., Kimani, J., et al. (2009) Levels of Innate Immune Factors in Genital Fluids: Association of Alpha Defensins and LL-37 with Genital Infections and Increased HIV Acquisition. AIDS, 23, 309-317.
http://dx.doi.org/10.1097/QAD.0b013e328321809c
[28] Feuerschuette, O.H.M., Silveira, S.K., Feuerschuette, I., Correa, T., Grando, L. and Trepani, Q. (2010) Recurrent Vaginal Candidiasis: Clinical Management. Femina, 38, 31-36.
http://files.bvs.br/upload/S/0100-7254/2010/v38n1/a005.pdf
[29] Corrales-Garcia, L.L., Possani, L.D. and Corzo, G. (2011) Expression Systems of Human β-Defensins: Vectors, Purification and Biological Activities. Amino Acids, 40, 5-13.
http://dx.doi.org/10.1007/s00726-010-0493-7
[30] Wallace, M.A., He, J.Q., Burkett, K.M., et al. (2006) Contribution of Alpha and Beta Defensins to Lung Function Decline and Infection in Smokers: An Association Study. Respiratory Research, 7, 76.
http://dx.doi.org/10.1186/1465-9921-7-76
[31] Ganz, T. (1999) Defensins and Host Defense. Science, 286, 420-421.
http://dx.doi.org/10.1126/science.286.5439.420
[32] Hackett, C.J. (2003) Innate Immune Activation as a Broad-Spectrum Biodefense Strategy: Prospects and Research Challenges. Journal of Allergy and Clinical Immunology, 112, 686-694.
http://dx.doi.org/10.1016/S0091-6749(03)02025-6
[33] Castaneda-Casimiro, J., Ortega-Roque, J.A., Venegas-Medina, A.M., et al. (2009) Péptidos antimicrobianos: Péptidos con múltiples funciones. Alergia, Asma e Inmunología Pediátricas, 18, 16-29.
http://www.medigraphic.com/pdfs/alergia/al-2009/al091d.pdf
[34] Ahn, J.K., Cha, H.S., Lee, J., Jeon, C.H. and Koh, E.M. (2012) Correlation of DEFA1 Gene Copy Number Variation with Intestinal Involvement in Behcet’s Disease. Journal of Korean Medical Science, 27, 107-109.
http://dx.doi.org/10.3346/jkms.2012.27.1.107
[35] Glenthoj, A., Glenthoj, A.J. and Borregaard, N. (2013) ProHNPs Are the Principal α-Defensins of Human Plasma of Human Plasma. European Journal of Clinical Investigation, 43, 836-843.
http://dx.doi.org/10.1111/eci.12114
[36] Bastian, A. and Schafer, H (2001) Human Alpha-Defensin 1 (HNP-1) Inhibits Adenoviral Infection in Vitro. Regulatory Peptides, 101, 157-161.
http://dx.doi.org/10.1016/S0167-0115(01)00282-8
[37] Lehrer, R.I. and Ganz, T. (2002) Defensins of Vertebrate Animals. Current Opinion in Immunology, 14, 96-102.
http://dx.doi.org/10.1016/S0952-7915(01)00303-X
[38] Kiehne, K., Brunke, G., Meyer, D., Harder, J. and Herzig. K.H. (2005) Oesophageal Defensing Expression during Candida Infection and Reflux Disease. Scandinavian Journal of Gastroenterology, 40, 501-507.
http://dx.doi.org/10.1080/00365520510015386
[39] Vento, G., Lio, A., Tirone, C., et al. (2013) Association of High Levels of α-Defensins and S100A Proteins with Candida Mannan Detection in Bronchoalveolar Lavage Fluid of Preterm Neonates. Pediatric Research, 74, 19-25.
http://dx.doi.org/10.1038/pr.2013.60
[40] Raj, P.A., Antonyraj, K.J. and Karunakaran, T. (2000) Large-Scale Synthesis and Functional Elements for the Antimicrobial Activity of Defensins. The Biochemical Journal, 347, 633-641.
http://dx.doi.org/10.1042/0264-6021:3470633
[41] Fan, S., Liu, X., Wu, C., Xu, L. and Li, J. (2015) Vaginal Nystatin versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis. Mycopathologia, 179, 95-101.
http://dx.doi.org/10.1007/s11046-014-9827-4
[42] Fan, S.R. and Liu, X.P. (2011) In Vitro Fluconazole and Nystatin Susceptibility and Clinical Outcome in Complicated Vulvovaginal Candidosis. Mycoses, 54, 501-505.
http://dx.doi.org/10.1111/j.1439-0507.2010.01887.x
[43] Martins, H.P., da Silva, M.C., Paiva, L.C., Svidzinski, T.I. and Consolaro, M.E. (2012) Efficacy of Fluconazole and Nystatin in the Treatment of Vaginal Candida Species. Acta Dermato-Venereologica, 92, 78-82.
[44] Mikamo, H., Matsumizu, M., Nakazuru, Y., Okayama, A. and Nagashima, M. (2015) Efficacy and Safety of a Single Oral 150 mg Dose of Fluconazole for the Treatment of Vulvovaginal Candidiasis in Japan. Journal of Infection and Chemotherapy, 21, 520-526.
http://dx.doi.org/10.1016/j.jiac.2015.03.011
[45] Fan, S., Liu, X. and Liang, Y. (2015) Miconazole Nitrate Vaginal Suppository 1200 mg versus Oral Fluconazole 150 mg in Treating Severe Vulvovaginal Candidiasis. Gynecologic and Obstetric Investigation, 80.
http://dx.doi.org/10.1159/000371759
[46] Sobel, J.D. (2015) Recurrent Vulvovaginal Candidiasis. American Journal of Obstetrics & Gynecology.
http://dx.doi.org/10.1016/j.ajog.2015.06.067
[47] Mendling, W. (2015) Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneous Candidosis). Mycoses, 58, 1-15.
http://dx.doi.org/10.1111/myc.12292

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.